Loading...
Innovator IBD ETF Leaders ETF
LDRS•AMEX
Financial Services
Asset Management
$28.27
$-0.15(-0.53%)
U.S. Market is Open • 15:29Innovator IBD ETF Leaders ETF (LDRS) AI-Powered Stock Analysis
See how Innovator IBD ETF Leaders ETF scores across key metrics like financial growth, valuation, and market position using AI-driven evaluation.
Model Information
The AI Stock Analysis Model is provided for informational purposes only and should not be considered financial advice. We are continously improving this model to increase accuracy and performance.Read our Full DisclaimerInnovator IBD ETF Leaders ETF (LDRS) Stock Overall Grade
Innovator IBD ETF Leaders ETF’s grade based on a comprehensive AI analysis of financial metrics, growth potential, and market position.
Z
Grade Breakdown by Metric
See how each financial and market factor contributes to Innovator IBD ETF Leaders ETF's overall stock rating.
Forecast
C+Score
53/100Financial Growth
CScore
40/100Fundamental Growth
C+Score
50/100Key Ratios
C+Score
55/100Sector Comparison
B+Score
75/100Industry Comparison
C+Score
50/100S&P 500 Benchmark
A+Score
94/100Analyst Consensus
C+Score
50/100Innovator IBD ETF Leaders ETF (LDRS) AI-Powered Stock Analysis
This asset demonstrates Normal performance with an overall Forecast Score of 53/100 (C+), reflecting weak confidence in its potential. Financial Growth (40/100, C) and Fundamental Growth (50/100, C+) highlight its stability, while Key Ratios (55/100, C+) and Sector Comparison (75/100, B+) indicate solid positioning. Compared to broader benchmarks like the S&P 500 (94/100, A+), it shows competitive strength. Analyst Consensus (50/100,C+) suggests High divergence in outlook.Component Analysis Explained
Understand the key factors behind each Innovator IBD ETF Leaders ETF stock grade, including financials, comparisons, and forecasts.